In Brief: Banner Pharmacaps/Chase Pharmaceutical
Banner Pharmacaps/Chase Pharmaceutical: Will build a new manufacturing facility and new corporate headquarters in High Point, N.C., the companies jointly announce Jan. 26. The new $35 mil. manufacturing facility for softgels and Softlets, gelatin coated tablets, is scheduled to be fully operational in 1996. The companies' Elizabeth and Newark, N.J. facilities will be closed in the next 15-18 months as production moves to the new facility. The 500 employees at the New Jersey facilities will be able to apply for positions at the new facility and will be granted a transfer allowance. Both companies are subsidiaries of the Dutch firm Sobel N.V...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth